SCHEMBL6967672

SCHEMBL6967672

CCc1ccccc1OCC1CCCc2[nH]cnc21

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
L3MBTL1 Q9Y468 5/20 0.43
MAPT P10636 3/20 0.43
NPSR1 Q6W5P4 1/20 0.43
TSHR P16473 3/20 0.39
HSD17B10 Q99714 1/20 0.39
NISCH Q9Y2I1 1/20 0.38
TP53 P04637 2/20 0.37
CYP1A2 P05177 2/20 0.37
CYP3A4 P08684 2/20 0.37
CYP2C19 P33261 2/20 0.37
MEN1 O00255 2/20 0.37
KMT2A Q03164 2/20 0.37
ADRB2 P07550 1/20 0.37
ADRB1 P08588 1/20 0.37
ADRB3 P13945 1/20 0.37
ADRA1A P35348 2/20 0.36
RAB9A P51151 2/20 0.36
CYP2D6 P10635 1/20 0.36
CYP2C9 P11712 1/20 0.36
THPO P40225 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6962416 0.84 METAP2 (0.44) L3MBTL1TSHRCYP1A2CYP2C19ADRA1A
SCHEMBL6966759 0.82 METAP2 (0.46) NISCHRAB9AHPGDKDM4E
SCHEMBL6961211 0.81 METAP2 (0.43) L3MBTL1TSHRCYP1A2CYP2C19ADRA1A
SCHEMBL6956610 0.77 ADRB2 (0.42) TSHRADRB2ADRB1ADRB3HPGD
SCHEMBL6964336 0.76 HTR1A (0.34) MEN1KMT2ALMNA
SCHEMBL6963222 0.74 METAP2 (0.44) MEN1KMT2ARAB9A
SCHEMBL6966902 0.72 PTGDR2 (0.39) MAPTTP53CYP1A2CYP3A4CYP2C19
SCHEMBL6967005 0.71 DPP4 (0.41) LMNA
SCHEMBL7006799 0.71 AOC3 (0.37) RAB9AAOC3LMNA
SCHEMBL6968558 0.71 LTA4H (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US claimed
US-6610721-B2 Imidazo heterocyclic compounds NOVO NORDISK A/S (DK) 2003-08-26 US disclosed
EP-1268483-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2003-01-02 EP disclosed
US-20010049385-A1 Imidazo heterocyclic compounds HIGH POINT PHARMACEUTICALS, LLC 2001-12-06 US disclosed
WO-2001068651-A1 CONDENSED IMIDAZOLES AS HISTAMINE H3 RECEPTOR LIGANDS NOVO NORDISK A/S (DK) 2001-09-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049385-A1 Imidazo heterocyclic compounds HRH4, HRH3, HRH2 L3MBTL1 3389/4885MAPT 1982/4885NPSR1 184/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.